
GLP-1 weight-loss drug Wegovy shows promise in cutting alcohol use among obese patients
A Danish randomized trial of 108 obese adults with alcohol use disorder found that 26 weeks of 2.4 mg semaglutide (Wegovy) reduced heavy drinking days from 17 to about 5 per 30 days and cut total alcohol intake from roughly 2,200 g to 650 g, suggesting GLP-1 therapies could complement treatments for alcohol use disorder alongside weight management.













